Pneumococcal Disease in Qatar

To evaluate the impact of Pneumococcal Conjugate Vaccine (PCV-13) on vaccine and non-vaccine serotypes causing both invasive and non-invasive diseases in Qatar. The study also assesses the overall prevalence and serotype distribution of S.pneumoniae nasopharyngeal carriage in both healthy and sick children below five years of age over a three-year period.
Funding Partners:
  • Hamad Medical Corporation
Program Partners:
  • CDC's National Center for Immunization and Respiratory Diseases
Program Location:
  • Qatar